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Abstract 
Background 
Remission and recovery rates for people with a First Episode Psychosis (FEP) 
remain uncertain.  
Aims 
We conducted a systematic review and meta-analysis to assess pooled prevalence 
rates of remission and recovery in FEP in longitudinal studies and conducted meta 
regression analyses to investigate potential moderators.  
Method 
Longitudinal studies with follow up greater than 1 year reporting data on remission or 
recovery rates in FEP were included.  
Results 
Seventy nine studies were included representing 19,072 FEP patients(mean 
age=26.9years,male=59.5%).The pooled rate of remission among 12,301 individuals 
with FEP was 57.9%(95%CI=52.7-62.9,n=60 studies,mean follow-up=5.5 years). 
Higher remission rates were moderated by studies from more recent years. The 
pooled prevalence of recovery among 9,642 individuals with FEP was 
37.9%(95%CI=30.0-46.5,n=35,mean follow-up=7.2 years). Recovery rates were 
higher in North America compared to other regions.   
 
Conclusions 
Our data suggest that remission and recovery rates in FEP may be more favourable 
than previously thought. We observed stability of recovery rates after the first two 
years, suggesting that a progressive deteriorating course of illness is not typical. 
While remission rates have improved over time, recovery rates have not, raising 
questions about the effectiveness of services in achieving improved recovery. 
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Introduction 
Psychotic disorders are marked by heterogeneity in terms of clinical presentation and 
outcome. 1 Historically, schizophrenia was conceptualised as a chronic, progressive 
deteriorating condition. However, there is increasing recognition that people with 
schizophrenia can experience symptomatic improvements and regain a degree of 
social and occupational functioning.2 Over the past 20 years there has been an 
increased focus on specialist early intervention services for first episode psychosis 
(FEP).3, 4 However, it remains unclear what the outcomes are for people with FEP 
(including those with first episode schizophrenia (FES) in terms of remission and 
recovery.  
To our knowledge, only 3 systematic reviews and 2 meta-analyses have considered 
recovery or remission in FEP and/or schizophrenia.5-9 The most recent systematic 
review and meta-analysis concluded that only 13.5% of schizophrenia patients met 
the criteria for recovery, though the follow up period is not given, and this review 
included both FES and multi episode schizophrenia patients.9 Multi episode patients 
include those with more chronic or treatment resistant illnesses, who would by 
definition be expected to have lower recovery rates.  
A systematic review in FEP identified ‘good’ outcomes for 42% of patients with 
psychosis and 31% of schizophrenia patients,7 while a later review of remission in 
FEP identified an average remission rate of 40% (range 17%-78%).6 These reviews 
in FEP have been limited by wide variety of outcome definitions used,7 in keeping 
with a paucity of identified studies using standardized definitions of remission or 
recovery, a small number of included studies,6 and no FEP review including a meta-
analysis.    
While naturalistic FEP outcome studies of increasing sophistication and duration 
have been published,10-13 the longer term outcomes for these patients in terms of 
remission and recovery rates remains uncertain. This deficiency in the literature is 
important, as, since the introduction of the Remission in Schizophrenia Working 
Group (RSWG) criteria for remission in 2005, many studies in FEP have sought to 
use the operationalized criteria for remission in schizophrenia.14  
We, therefore, conducted a systematic review and meta-analysis to assess pooled 
prevalence rates of remission and recovery in FEP and FES in longitudinal studies. 
In addition, we sought to identify potential moderators of remission and recovery. 
Finally, we sought to investigate if specific variables have an impact on remission 
and recovery proportions (e.g. narrow and broad remission and recovery definitions, 
duration of follow-up, region of study and the study year).   
Our a priori hypotheses were the following:  
1. A greater proportion of patients with FEP will meet criteria for remission and 
recovery in studies from the past twenty years compared to earlier studies. 
2. Recovery will be less prevalent in samples with longer duration of follow-up 
compared with shorter follow-up.  
3. Rates of remission and recovery will be lower with the use of narrow criteria 
for defining remission and recovery. 
  
Methods 
This systematic review was conducted in accord with the Meta-analysis of 
Observational Studies in Epidemiology guidelines 15 and the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses standard.16 
Inclusion criteria  
We included studies of longitudinal observational design (both retrospective and 
prospective studies) in patients >16 years old (with no upper age limit) that fulfilled 
the following criteria: 
A) i) reporting remission rates and/or ii) recovery rates in people with a FEP 
(including FES and first episode affective psychosis) irrespective of clinical setting 
(inpatient, outpatient or mixed).  
Remission has been operationalized in terms of symptomatic and/or functional 
improvement with a duration component. The use of the Remission in Schizophrenia 
Working Group (RSWG) criteria has become common over the past decade 
measuring both an improvement in symptoms and duration criteria (>6 months) for 
persistence of mild or absent symptoms.14  
For remission, we categorised remission criteria into broad and narrow criteria for 
defining remission. Those studies in which remission was defined by the RSWG 
criteria (composed of two dimensions, accounting for symptom severity (mild or 
absent) and a duration criterion of mild or absent symptoms of ≥6 months) or if 
defined as patients being asymptomatic & attaining pre-morbid functioning sustained 
for ≥6 months, were classified as narrow criteria for remission. Those studies which 
defined symptomatic remission, but not a duration were classified as broad criteria.  
Recovery has been operationalised as a multidimensional concept, incorporating 
symptomatic, and functional improvement in social, occupational and educational 
domains, with a necessary duration component (>2 years).9, 17, 18  For recovery, we 
mirrored the approach of Jääskeläinen et al., 2013, categorising those studies in 
which both clinical and functioning dimensions are operationally assessed, along with 
a duration of sustained improvement for ≥2 years.9  We further analysed recovery in 
relation to those studies in which both clinical and level of functioning dimensions 
were assessed, but with a duration for sustained improvement of >1 year. We 
categorised as broad recovery criteria those studies in which either one or none of 
the symptom improvement and functioning dimensions were used and/or with an 
insufficient duration criterion 
B) People with FEP who were making their first treatment contact (in both inpatient 
and outpatient settings)  
C) Using a specified standardized diagnostic system (e.g. ICD (International 
Classification of Diseases, versions 8,9 and 10), DSM (Diagnostic and Statistical 
Manual of Mental Disorders (DSM versions III and IV), Kraepelin & Feighner’s 
diagnostic criteria, Royal Park Multidiagnostic Instrument for Psychosis, and the 
Research Diagnostic Criteria (RDC)   
D) Study sample that included 100% individuals with FEP, and/or FES and/or first 
episode affective psychosis. When more than one diagnostic group was identified in 
a sample, that study was only included if the number in each subgroup was identified 
E) A follow up period of > 12 months  
F) Studies with adequate follow up data to allow for remission or recovery rates to be 
determined (e.g. studies only reporting mean difference in symptom rating scales 
between groups or correlations were excluded)  
G) Articles published in a peer reviewed journal from database inception to July 
2016, with no language restrictions applied 
 
Exclusion criteria 
Exclusion criteria were:  
A) Randomized controlled trials (RCTs) due to the potential for any structured 
intervention beyond routine care to influence our primary outcomes    
B) Studies of organic psychosis.  
Search criteria 
Two independent authors (JL, OA) searched PubMed, Medline, and Scopus without 
language restrictions from database inception until July 1, 2016. Key words used 
were “first episode psychosis” OR “early episode psychosis” OR “schizophrenia” OR 
“schiz*” AND “remission” OR “recovery” AND “outcome” OR “follow-up”. Manual 
searches were also conducted using the reference lists from recovered articles and 
recent reviews.6, 7, 9 
Data Extraction 
Two authors (JL and OA) extracted all data, and any inconsistencies were resolved 
by consensus or by a third author (BS). One author (OA) extracted data using a 
predetermined data extraction form, which was subsequently validated by a second 
author (JL). The data extracted included first author, country, setting, population, 
study design (e.g. prospective, retrospective), participants included in the study 
(including mean age, % female), diagnostic classification method, method of 
assessment (e.g. face-face interviews, case records, or combination of both 
approaches), duration of untreated psychosis (DUP), socio-demographic 
characteristics of the sample employed in the study (e.g., % employed, single or in 
stable relationship at the study entry), baseline psychotic symptoms (mean scores), 
length of study follow up, participant loss at follow up, and criteria used to define 
remission and recovery. When studies reported on overlapping samples, details of 
the study with the longest follow up were included, or if this was unclear, studies with 
the largest study sample for each respective outcome were included. We included 
multi-site studies, and retained data for the entire cohort and not for individual sites. 
Primary outcomes 
The co-primary outcomes were the proportion of people with FEP who met the 
criteria for a) remission and b) recovery over the course of each study as defined 
above.  
 
Statistical analysis 
Due to the anticipated heterogeneity across studies, we conducted a random effects 
meta-analysis. The meta-analysis was conducted in the following sequence. First, we 
calculated the pooled prevalence rates of remission and recovery in FEP. Second, in 
order to account for attrition bias, we imputed a remission and recovery rate using 
the principle of worst case scenario assuming all people who dropped out did not 
have a favourable outcome. Third, we calculated the subgroup differences in 
remission and recovery according to whether a narrow or broad definition of 
remission or recovery was used, the first episode diagnosis category, the method 
used to assess remission and recovery (structured face-to-face assessment; 
structured assessment supplemented with clinical notes and/or interviews with 
parents; clinical records), duration of follow-up (categorised into three groups: 1-2 
years; 2-6 years; >6 years based on ascending duration of follow-up (tertiles)), region 
of study, the study period (we selected the midpoint of the study period as the study 
year, and categorized this by adapting criteria proposed by Warner et al. 5 for 
recovery studies-pre 1975; 1976-1996; 1997-2016; and for remission studies-pre 
1975; 1976-1996; 1997-2004; 2005-2016), the study design, and the setting of the 
study at FEP (inpatient; community & early intervention services; and mixed in-and 
out-patient psychiatric services). 
Fourth, we conducted meta-regression analyses to investigate potential moderators 
of remission and recovery (age, percentage of males, ethnicity, baseline psychotic 
symptoms (mean scores), relationship and employment status at first contact, DUP, 
duration of follow up, attrition rate and study year.  
Publication bias was assessed with the funnel plot, Egger regression test,19 and the 
“trim and fill” method. 20  
Heterogeneity was measured with the Q statistic, yielding a chi-square and p-value, 
and the I2 statistic with scores above 50% and 75% indicating moderate and high 
heterogeneity.21 
Finally, descriptive statistical methods were used for the exploratory summary of 
study- reported correlates of remission and recovery based on patient-level data not 
available for study-level meta-regression analyses. 
All analysis was conducted with Comprehensive Meta-Analysis software (CMA, 
Version 3) and STATA release 14 (STATACorp LP, USA). 
Results 
 
Search results and included participants  
Our search yielded 3021 non-duplicated publications, which were considered at the 
title, and abstract level; 299 full texts were reviewed, of which 79 met inclusion 
criteria (Figure 1).10-13, 22-96 Full details of the included studies are included in 
supplementary table 1 (studies with remission as outcome) and supplementary table 
2(studies with recovery as outcome). There were 44 studies reporting on remission 
rates and 19 reporting on recovery rates, with 16 studies reporting on both remission 
and recovery, for an overall of 79 independent samples. The final sample comprised 
19,072 FEP patients (range of sample sizes: 13-2,842), with 12,301 (range sample 
sizes 13-2,210) with remission data and 9,642 (range of sample sizes 25-2,842) with 
recovery data.  
 
Remission sample: The mean age of the patients at study recruitment was 26.3 
years (median 25.7 years, age range 15.6-42.3) and 40.6% were females. The mean 
DUP (N=25 studies) was 433.2 days (SD=238.9, IQR=265.0-541.4). The mean 
follow-up period was 5.5 years (N=60, 66.0 months, SD=5.3, IQR=2.0-7.0).  
 
Recovery sample: The mean age of the patients at study recruitment was 27.3 years 
(median 26.0 years, range 24.2-28.5) and 41.1% were female. The mean DUP 
(N=11 studies) was 359.2 days (SD=215.4, IQR=226.3-492.8). The mean follow-up 
period was 7.2 years (N=35, 86.4months, SD=5.6, IQR=2.0-10.0).  
 
Meta-analysis of remission and recovery:  
Rate of remission 
The pooled rate of remission among 19,072 individuals with FEP was 57.9% (95% 
CI=52.7-62.9, Q=1536.3, p<0.001, N=60)(see Figure S1 in the online data 
supplement). The Begg-Mazumdar (Kendall's tau b=0.151, p=0.09) and Egger test 
(bias=0.98, 95% CI=-1.423.38, p=0.47) indicated no publication bias. A visual 
inspection of the funnel plot revealed that there was some asymmetry in the plot, and 
we adjusted for this asymmetry and potential missing studies (see FigureS1 in the 
online data supplement). The trim-and-fill method demonstrated that the prevalence 
of remission was unaltered when adjusted for potential missing studies. Restricting 
the analysis to studies which used the RSWG criteria for remission (N=25 studies, 
N=6,909 patients), the overall pooled prevalence remission rate was 56.9% (95% 
CI=48.9-64.5, Q=656.9, N=25 studies). Using the worst case scenario, the remission 
rate was 39.3% (95% CI=35.1-43.5, Q=1371, N=55 studies).  
 
Subgroup analyses of remission rates 
Full details of the proportion of people who experienced remission, together with 
heterogeneity and trim and fill analyses are summarized in Table 1. Results of 
interest are briefly discussed below.  
Insert table 1 here 
For those studies with FES patients only, the pooled remission rate was 56.0% (95% 
CI=47.5-64.1, Q=378.50, N=25 studies), with an equivalent rate of 55.4% (95% 
CI=47.7-62.8, Q=1049.0, N=29 studies) for FEP patients; the pooled remission rate 
was higher in FE affective psychosis only patients (78.7%, 95% CI=63.9-88.5, 
Q=68.6, N=6 studies) compared to people with FES.  
There were no differences in remission rates by the study period, duration of study 
follow up, study type or setting, or proportion of studies using narrow remission 
criteria. Remission rates were significantly higher in studies from Africa (73.1%, 95% 
CI=47.2-89.1, Q=2.48, N=2 studies), Asia (66.4%, 95% CI=55.8-75.5, Q=139.2, N=2 
studies) and North America (65.2%,95% CI=56.6-72.9, Q=192.7, N=17 studies) 
compared to other regions (including Europe and Australia). 
Meta regression of factors influencing remission rates 
Full details of the moderators of remission are presented in Table 2. Higher 
remission rates were associated with studies conducted in more recent years 
(β=0.04, 95% CI=0.01-0.08, p=0.018, R2=0.10). 
Insert table 2 here 
Rate of recovery 
Full details of the proportion of people who are recovered, together with 
heterogeneity and trim and fill analyses are summarized in Table 3.  
Insert table 3 here 
The pooled rate of recovery among 9,642 individuals with FEP was 37.9% (95% 
CI=30.0-46.5, Q=1450.8, N=35 studies, p=0.006) (see Figure S3 in the online data 
supplement). The Begg-Mazumdar (Kendall's tau b=-1.0, p=0.37) and Egger test 
(bias=2.32, 95% CI=-1.77 – 6.42, p= 0.25) indicating no publication bias. A visual 
inspection of the funnel plot revealed that the plot was largely symmetric (see Figure 
S4 in the online data supplement).The trim-and-fill method demonstrated that the 
prevalence of recovery was unaltered when adjusted for potential missing studies. 
Assuming the worst case scenario technique, the pooled prevalence of recovery was 
23.3% (95% CI=18.4-29.2, Q=1270, N=33 studies).  
 
Subgroup analyses of recovery rates 
For those studies using the narrowest recovery criteria, the recovery rate was 25.2% 
(95% CI=16.87-35.93, Q=885.45, N=16 studies). Further, the pooled prevalence of 
recovery was significantly higher in North America (Canada and USA) (71.0 %, 95% 
CI=56.8-82.0, Q=150.1, N=10 studies, p<0.001) than Europe (21.8%, 95% CI=14.6-
31.2, Q=434.2, N=14 studies), Asia (35.1%, 95% CI=22.1-50.7, Q=184.5, N=8 
studies) and Australia (28.1%, 95% CI=10.0-57.9, Q=1.45, N=2 studies). Following 
the trim and fill analysis the recovery rate from North America decreased slightly to 
68.5% (95% CI=48.6-83.4); there was a slight increase in the recovery rate seen in 
studies from Europe to 26.3% (95% CI=16.6-38.9). There were no significant 
difference in North American studies compared to studies from other regions in 
relation to attrition rate, average length of follow up (mean duration of follow up: 
North America 4.7 (SD=4.1) years vs other regions 7.8 (SD=5.8) years (t=-1.46, 
p=0.15), or the use of more narrow recovery criteria (although no studies North 
America used a recovery criterion of >2 years duration, compared to 8 studies from 
other regions which used this criterion (x2=2.77, p=0.052)). Additionally, those 
studies with the longest follow up periods (>6 years) (32.4%, 95% CI=23.4-43.0, 
Q=250.5, N=15 studies) and with a 2-6 year follow up (32.30%, 95% CI=21.5-45.3, 
Q=462.0, N=11 studies) had significantly lower recovery rates than those studies 
with a 1-2 year follow up (54.1%, 95% CI=39.0-68.4, Q=167.0, N=9 studies) 
(p=0.044).  
Equivalent rates of recovery were found in those with FEP (34.4%) and FES (30.3%) 
diagnoses. Those with a diagnosis of FE affective psychosis had a significantly 
increased pooled recovery rate (84.6%, 95% CI=64.0-94.4, Q=109.3, N=4 studies) 
compared to those with FEP (34.4% (95% CI: 25.2-44.9, Q=527.0, N=19 studies), 
and FES (30.3% (95% CI=19.7-43.6., Q=514.7, N=12 studies) (p=0.0031).  
 
Meta regression of factors influencing recovery rates 
Full details of the moderators of recovery are presented in supplementary table 3. 
Briefly, the meta regression analyses showed that higher rates of recovery were 
moderated by White ethnicity (β=0.02, 95% CI=0.01-0.04, p=0.002, R2=0.41); 
whereas, lower rates of recovery were moderated by Asian ethnicity (β=-0.02, 
95%CI=-0.04-0.00, p=0.019, R2=0.32) and a higher loss to attrition (or drop-out 
rates) (β=-0.04, 95%CI=-0.07- -0.01, p=0.009, R2=0.21).  
Discussion 
 
This novel, large scale meta-analysis found that fifty-eight percent of FEP patients 
meet criteria for remission and 38% meet criteria for recovery over a mean of 5.5 and 
7.2 years follow up respectively. Thirty percent of those with FES met the criteria for 
recovery. Our findings are particularly relevant given the previously reported lower 
rates of recovery in multi episode schizophrenia of 13% 9. The average duration of 
follow up of 5.5 years in our remission sample and 7.2 years in our recovery cohort 
adds further weight to the significance of our findings.  
Remission  
Our findings for remission were remarkably stable and did not differ dependent on 
the use of more stringent criteria such as the RSWG (57%) or the use of broader 
criteria (59%). Our remission rate of 57% based on studies using the RSWG criteria, 
is higher than the rate of 40% identified in a systematic review from 2012. 6  Our 
study improves on this previous review by the inclusion of 25 studies using the 
RSWG criteria to define remission, as compared to 12 studies, and by having a 
longer average duration of follow up.  
Few variables were found to be moderators of remission rates, and no patient level 
clinical or demographic variables were associated with remission. We identified that 
a more recent study period was associated with improved remission rates, perhaps 
reflecting the improved outcomes from FEP patients treated in dedicated early 
intervention services over the past two decades. 
Recovery 
Our identified rate of recovery of 38% in FEP is higher than previously identified rates 
of 13.5% and 11-33% in multi episode schizophrenia.5, 9 Our imputed recovery rate of 
23% based on the worst case scenario technique is equivalent to the recovery rate 
for those studies which defined recovery based on symptomatic and functional 
improvement sustained for more than 2 years. Further, this worst case scenario 
recovery rate of 23% remains higher than that identified in most recent review of 
multi episode schizophrenia outcomes by Jääskeläinen et al. Our pooled recovery 
rate is similar to the 42% who showed functional recovery in the systematic review of 
outcome in FEP by Menezes et al., though this ‘good’ outcome was based on data 
from 11 studies only,7 whereas we included 39 studies with recovery as an outcome. 
Further, in the review of Menezes et al, the ‘good’ outcome measure was based on 
an average follow period of 3 years, much shorter than our 7 year follow up. In our 
review, we report on studies with standardized definitions of recovery and 
comparisons between those with strict and broad definitions of recovery- in contrast 
to the Menezes et al, review, in which studies reporting on a wide variety of outcome 
measures (including some with definitions of remission and recovery) were combined 
into good, intermediate, and poor outcomes. 7 
One interesting finding is the significantly increased pooled prevalence of recovery 
identified in North America (Canada and USA) compared to all other regions. This 
regional variation in recovery was not accounted for by statistically significant 
differences in baseline clinical and demographic variables, or dropout rates. We 
identified that none of the North American studies used the more conservative two-
year criterion to define recovery, compared to 32% (N=8) of studies from other 
regions, and only 11% (N=1) of North American studies had a follow up of longer 
than 6 years, compared to 52% (N=13) from other regions, differences which trended 
towards significance, and which potentially impacted on the improved recovery rate 
from this region. This finding warrants further investigation. It may be related to 
differences in the types of patients with FEP who were enrolled in North America 
compared to other regions.  There may be other service level confounds which we 
were unable to investigate, such as an increased proportion of studies in North 
America occurring in academic centres, in which the potential for more intensive and 
multimodal treatment approaches may have been available.  However, we were 
unable to assess the effects of variable treatments by region which may have 
contributed to improved recovery rates in North America. Further, the influence of 
potential non-representative sampling in North America 97 could not be accounted 
for.  
We demonstrated for the first time in a large scale meta-analysis that recovery in 
FEP is not reduced with a longer duration of follow up. This finding, contrary to one of 
our hypotheses, was interesting, in that those with a follow up period greater than 6 
years (32% recovery rate) and those with a 2-6 year follow up (32% recovery rate), 
had equivalent rates of recovery, indicating that the rate of recovery seen from 2-6 
years, can be maintained for patients followed up beyond 6 years. This is in contrast 
to previous reviews that found an association between longer follow up duration and 
reductions in ‘good’ outcomes.7, 8 If psychotic disorders, and more specifically 
schizophrenia are progressive disorders, then we might expect to see decreased 
recovery rates with longer periods of follow up. The fact that we have not identified 
any changes in recovery rates after the first two years of follow up indicates an 
absence of progressive deterioration. This suggests that patients with worse 
outcomes are apparent in the earlier stages of illness, rather than that the course of 
illness been a progressive one for the majority of patients.98 This is supported by 
recent evidence indicating that treatment resistance in schizophrenia is present from 
illness onset for the majority who develop a treatment resistant course of illness. 99 
 
We hypothesised that a greater proportion of cases of FEP would have recovered in 
recent years. However, similar to earlier reviews in multi episode patients (and in 
contrast to our findings in relation to remission rates), we did not identify that 
recovery rates were increasing over time.5, 8, 9 In fact, we identified a significantly 
reduced pooled recovery rate for studies conducted from 1997-2016 (32%) 
compared to the pooled recovery rate of 45% for studies conducted from 1976-1996. 
This finding in a FEP population indicates that thus far the dedicated and intensive 
specialist care provided for FEP patients over the past two decades has not resulted 
in improved recovery rates, even though remission rates were improved over the 
past two decades.  
 
Knowledge of factors associated with increased recovery in FEP can help identify 
individuals in need of more robust interventions. However, we found few moderators 
of recovery in our meta-analysis. White ethnicity was associated with increased 
recovery, whereas Asian ethnicity was associated with lower recovery rates.  Higher 
dropout rates moderated lower recovery, potentially indicative of a selection bias, in 
that those who are well, and are no longer in contact with mental health services may 
be disproportionately lost to follow up, thus impacting on the recovery rate.  
Duration of Untreated Psychosis 
A longer DUP was not a moderator of remission or recovery rates. This was a 
secondary outcome measure in our study, but despite that our findings are contrary 
to previous meta-analyses, which found that a shorter duration of untreated 
psychosis is associated with better outcomes.100  
Strengths and Limitations 
While this is the first meta-analysis of remission and recovery in FEP, including a 
large data set of 19,897 FEP patients, we acknowledge some limitations.  
First, there was considerable methodological heterogeneity across studies. 
Consequently, we encountered high levels of statistical heterogeneity, which is to be 
expected when meta-analysing observational data.15 We followed best practice in 
conducting subgroup and meta regression analyses to explore potential sources of 
heterogeneity.  However, the main results do not appear to be influenced by 
publication bias, and were largely unaltered after applying the trim-and-fill method. 
Further, for remission there was little variability in the overall rates of remission by 
definition of remission, study type and method of assessment used. Though the 
different definitions of recovery can provide an inflated rate of recovery, we provided 
data relating to studies with the most stringent criteria for recovery with symptomatic 
and functional recovery for more than 2 years (with an identified recovery rate of 
22%).  We further provided a worst case scenario rate for remission and recovery, 
imputing these values based on the trial number of recruited patients, and assuming 
that all those lost to follow up would not have met criteria for remission or recovery. 
Our findings therefore, offer valid measures of remission and recovery in FEP.  
Second there was inadequate data on important confounders such as treatments 
given over the course of follow up, adherence with treatment, social functioning and 
symptom profile over the course of follow up, and lifestyle factors such as alcohol 
and substance use, precluding the meta analytic assessment of these factors as 
moderating or mediating variables. Future studies may wish to consider including 
data from intervention studies in FEP, to assess the influence of specific treatments, 
and adherence to treatment on remission and recovery rates in FEP.101 
Third, data for this meta-analysis was extracted from baseline and follow up points 
from the individual studies, with limited information available in individual studies for 
the period during the follow up.  
Fourth, while remission and recovery rates are provided at study endpoint, no data is 
available on those who met, and sustained criteria for remission or recovery for the 
entire duration of follow up, nor at what time point individuals met criteria for 
remission or recovery. The absence of such data does not allow for a more detailed 
description of illness trajectory. However, we have been able to delineate the effects 
of duration of study follow up on remission and recovery.  
Fifth, while we identified studies from six regions of the world, there was marked 
variability in the number of studies from each region, with the majority of studies 
conducted in North America and Europe.  In relation to the higher rate of recovery 
identified in North America compared to other regions, we cannot rule out 
confounding variables relating to differences in the types of patients with FEP who 
were enrolled in North America compared to other regions, and other service level 
confounds which may have existed between regions.  However, our finding of lower 
remission rates in Europe is consistent with findings from the prospective W-SOHO 
study on the outcome for multi-episode schizophrenia in an out-patient setting.102 
Finally, consideration for the introduction of sampling bias due to the variability at the 
point of recruitment to FEP studies is required. Some may recover quickly from a 
FEP and not wish to participate, others may be severely unwell and unable to 
consent to participate, while community based FEP studies may be unable to recruit 
patients with more chaotic presentations.  
Conclusions 
This is the first meta-analysis of remission and recovery rates, and moderators of 
these outcomes, in people with FEP, and the first meta-analysis pooling and 
comparing all available data across patients with FEP, FES and first episode 
affective psychosis. We provide evidence of higher than expected rates for remission 
and recovery in FEP. We confirm that recovery rates stabilise after the first two years 
of illness, suggesting that psychosis is not a progressive deteriorating illness state. 
While remission rates have improved over time, rates of recovery have not done so, 
potentially indicating that specialised FEP services in their current incarnation, while 
improving remission rates, have not provided improved longer term recovery rates. 
Our study highlights a better long term prognosis in FEP and FES, and a more 
positive outlook for people diagnosed with FEP and FES, than has been suggested 
by previous studies, which included patients with multi episode schizophrenia. 
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